A father's battle with a rare and aggressive form of thyroid cancer has left him facing a grim future unless he can afford a life-saving medication. Clinton, a 42-year-old father of three, was diagnosed with medullary thyroid carcinoma 10 years ago. He found a medication called selpercatinib that has been a miraculous treatment for him. However, the drug is not subsidized for his specific type of cancer, and he is now facing a difficult choice: either continue taking the medication and pay $8,000 per month or stop and face a shortened life expectancy. The Pharmaceutical Benefits Advisory Committee will consider listing selpercatinib at its meeting next month, but the process has already been delayed once and any outcome will take months. The Australian Government must urgently increase investment in the Pharmaceutical Benefits Scheme (PBS) to ensure that Australians, like Clinton, can access life-changing medicines. Clinton's story is a heartbreaking illustration of how broken the PBS is, and it highlights the need for faster access to cutting-edge medicine and treatments. The Health Minister Mark Butler has been approached to intervene, but with no luck. Eli Lilly, the pharmaceutical company that had been supplying Clinton with his medication on compassionate grounds, says his story is an illustration of how broken the PBS is. Clinton is not asking for free treatment, but rather for a more fair and affordable way to access the medication he needs. The controversy surrounding Clinton's case raises important questions about the accessibility and affordability of life-saving medications in Australia. What do you think? Do you agree or disagree with Clinton's situation? Share your thoughts in the comments below.
